<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00378976</url>
  </required_header>
  <id_info>
    <org_study_id>21760-A</org_study_id>
    <secondary_id>AI277S7;AI38858;AI30731</secondary_id>
    <nct_id>NCT00378976</nct_id>
  </id_info>
  <brief_title>HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1, HSV-2 Co-infected Men.</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Crossover Trial of Valacyclovir for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Coinfected Men Who Have Sex With Men (MSM).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociación Civil Impacta Salud y Educación, Peru</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Over 80% of HIV-1 infected persons are also seropositive for HSV-2. Increasingly, clinical&#xD;
      and epidemiologic evidence show the role of HSV in increasing HIV infectiousness. The&#xD;
      evidence suggests that that HSV is an important cofactor in HIV transmission.&#xD;
&#xD;
      The trial's purpose is to assess the reduction in HIV shedding associated with valacyclovir&#xD;
      for suppression of HSV-2 reactivation.&#xD;
&#xD;
      This proof-of-concept, randomized, double-blind, placebo controlled crossover trial of 20&#xD;
      HIV/HSV-2 co-infected men, assessed the effects of daily valacyclovir on HIV-1 levels in the&#xD;
      plasma and rectal mucosa secretions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Herpes simplex virus type 2 (HSV-2) is common among HIV infected persons. HSV-2 reactivation&#xD;
      is associated with increased plasma and genital HIV-1 levels, and in vitro, HSV-2 upregulates&#xD;
      HIV transcription.&#xD;
&#xD;
      The trial assessed whether HSV-2 suppression reduces rectal and plasma HIV-1 levels in HIV-1,&#xD;
      HSV-2 co-infected men who have sex with men (MSM).&#xD;
&#xD;
      Conducted in Lima Peru, 20 antiretroviral naive HIV-1 and HSV-2 seropositive MSM with CD4&#xD;
      &gt;200 were randomly assigned to receive valacyclovir 500 mg bid or placebo for 8 weeks, than a&#xD;
      2 week washout period, followed by the alternative regimen for 8 weeks. Men collected daily&#xD;
      home anogenital swabs for HSV DNA PCR, had three weekly anoscopy procedures for collection of&#xD;
      rectal mucosal secretions for HIV-1 RNA, HSV DNA, and weekly plasma HIV-1 RNA by PCR.&#xD;
      Outcomes were plasma and rectal HIV-1 levels by study arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in anogenital HIV-1 shedding with suppression of HSV-2 reactivation.</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate HSV-2 suppression with decreased plasma HIV RNA levels</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the effect of daily valacyclovir on pharyngeal shedding in HSV-1 seropositive individuals</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the temporal pattern of HIV shedding in the rectum, pharynx and semen with respect to mucosal HSV-1 and HSV-2 reactivation; Determine HSV-2 suppression and HIV replication within rectal mucosa.</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV Infection</condition>
  <condition>Herpes Simplex</condition>
  <condition>Sexually Transmitted Diseases</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <description>500 mg twice-daily oral</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>matching placebo</intervention_name>
    <description>twice daily as per experimental drug</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Greater than 18 years old,&#xD;
&#xD;
          -  Documented HIV-1 seropositive,&#xD;
&#xD;
          -  CD4 count greater than 200,&#xD;
&#xD;
          -  Not on HIV antiretroviral therapy,&#xD;
&#xD;
          -  HSV-2 seropositive as determined by Focus EIA (IN &gt;3.5)&#xD;
&#xD;
          -  Not intending to move out of the area for the duration of study participation.&#xD;
&#xD;
          -  Willing and able to:provide independent written informed consent;undergo clinical&#xD;
             evaluations;take study drug as directed;adhere to follow-up schedule.&#xD;
&#xD;
          -  Bacterial STDs (symptomatic STD syndromes or laboratory-confirmed asymptomatic&#xD;
             gonorrhea and syphilis) are treated within two weeks of study enrollment and random&#xD;
             assignment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        MSM who meet any of the following criteria are not eligible for this study:&#xD;
&#xD;
          -  Known history of adverse reaction to valacyclovir, acyclovir or famciclovir;&#xD;
&#xD;
          -  Planned open label use of acyclovir, valacyclovir, or famciclovir&#xD;
&#xD;
          -  Known medical history of seizures&#xD;
&#xD;
          -  Known renal failure, serum creatinine &gt;2.0mg/dl&#xD;
&#xD;
          -  Hematocrit &lt; 30 %&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Connie Celum, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asociacion Civil Impacta Salud y Educacion</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>September 19, 2006</study_first_submitted>
  <study_first_submitted_qc>September 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2006</study_first_posted>
  <last_update_submitted>August 21, 2013</last_update_submitted>
  <last_update_submitted_qc>August 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2013</last_update_posted>
  <responsible_party>
    <name_title>Connie Celum, MD, MPH</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>HIV infection</keyword>
  <keyword>HIV shedding</keyword>
  <keyword>HSV suppression</keyword>
  <keyword>Co-infected</keyword>
  <keyword>MSM</keyword>
  <keyword>Reactivation</keyword>
  <keyword>Valacyclovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Herpes Simplex</mesh_term>
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

